Navigation Links
Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD
Date:10/19/2011

ASHBURN, Va. ,Oct. 19, 2011 /PRNewswire/ -- Innocoll, Inc. announced it has entered into a License and Distribution Agreement with Pioneer Pharma in China for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery.  

Dr. Michael Myers, President and CEO stated "This is an exciting development for Innocoll. China is becoming an increasingly important and dynamic market for medical products and we are very pleased to have established this partnership with such an innovative company as Pioneer.  I look forward to exploring additional partnership opportunities between our two companies."  

Mr. XinZhou Li, President and CEO from Pioneer Pharma stated "We are very excited to have finally reached the partnership agreement with Innocoll. Let us mark this day with remembrance as CollaGUARD will become a very important product in our current distribution channel. We believe that CollaGUARD® has significant market potential and Pioneer will try to make it happen. "

About CollaGUARD®

CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy.  When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (< 0.001) and significantly reduced the extent and severity of adhesions (< 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and antiadhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.

About Postoperative Adhesions

Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membrane as a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.

About Pioneer

Pioneer Pharma, founded in Hainan in 1996, imports and distributes high-end pharmaceutical products into China.  Pioneer markets and distributes over 30 products across a wide range of therapeutic categories on behalf of its strategic partners and has filed over 10 additional products that are pending approval.  The company has over 34 representative offices across China and covers over 7,500 hospitals and 40,000 drugstores.  

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPress™ and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 2b for the management of post-operative pain. For more information, please visit www.innocollinc.com.

CONTACT: Veronica Kelly, +353 9064 86834, vkelly@innocoll-pharma.com


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
2. Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
3. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
4. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
5. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
6. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in ... of contaminated well water throughout the Houston area. , Heavy floodwaters have led to ... exposed to contaminants. Residents may not even be aware of the contamination of their ...
(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... and tick-borne disease research and education, today announced that it has named Scott ... of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in helping ... bites and how to avoid being bitten this spring. , The official tick ... Ticks, small spider-like insects, are known for attaching themselves to their prey while they ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications ... multiplex immunoassays are widely used for cell and protein analysis. Keeping updated on ... quality and efficiency in these areas. , LabRoots introduces a new complementary ...
Breaking Medicine News(10 mins):